Share Price and Basic Stock Data
Last Updated: December 6, 2025, 10:30 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zota Health Care Ltd operates within the pharmaceuticals sector, focusing on the manufacture and distribution of various healthcare products. The company’s revenue trajectory has shown a mix of growth and volatility in recent reporting periods. For instance, Zota reported sales of ₹139 Cr for FY 2023, which marked a modest increase from ₹131 Cr in FY 2022. However, the subsequent FY 2024 is projected to rise significantly to ₹180 Cr, indicating an optimistic shift in sales momentum. This upward trend continued into the trailing twelve months, where revenue reached ₹340 Cr. The quarterly sales data further underscores this growth, with Q2 FY 2024 sales reaching ₹45 Cr and Q3 expected to climb to ₹47 Cr. However, the company has faced challenges in managing its expenses, which have also escalated, leading to concerns about the sustainability of its profit margins.
Profitability and Efficiency Metrics
Profitability has been a significant concern for Zota Health Care. The company recorded a net loss of ₹58 Cr for FY 2025, a stark contrast to the ₹9 Cr profit reported in FY 2022. This decline in profitability is alarming, especially considering the operating profit margin (OPM) stood at a meager 4% in FY 2024, down from 11% in FY 2022. The operating profit has consistently fluctuated, with negative operating profits reported in the latter part of FY 2024. Moreover, the interest coverage ratio is troublingly low at -0.33x, indicating that the company is struggling to meet its interest obligations. The cash conversion cycle (CCC) of 219 days indicates inefficiencies in managing inventory and receivables, which could be a drag on cash flow and operational performance moving forward.
Balance Sheet Strength and Financial Ratios
Zota’s balance sheet reveals a complex picture. The company reported total borrowings of ₹181 Cr against reserves of ₹285 Cr, suggesting a reasonable debt-to-equity ratio of 0.02. This low leverage indicates a conservative approach to borrowing, which can be seen as a strength. However, the current ratio of 1.83 suggests that while the company can cover its short-term obligations, the low interest coverage ratio raises red flags about its overall financial health. The price-to-book value ratio of 10.31x is quite high, which could indicate that the stock is overvalued relative to its book value. Investors might view this with caution, especially given the recent performance metrics. The return on equity (ROE) of 36% appears strong, but the declining trend in profitability could erode this figure if losses persist.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Zota Health Care reflects a significant level of promoter control, with promoters holding 55.81% of the company as of September 2025. This high percentage can instill confidence in retail investors, suggesting that the founders have a vested interest in the company’s success. However, it’s noteworthy that foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have only a modest presence at 3.49% and 4.95%, respectively. This limited institutional interest may point to concerns regarding the company’s financial stability and growth prospects. Additionally, the number of shareholders has increased to 11,855, indicating a growing interest from the public. However, the declining trend in promoter shareholding from 68.12% in December 2022 to 55.81% may raise questions about insider confidence in the company’s future.
Outlook, Risks, and Final Insight
Looking ahead, Zota Health Care faces a dual-edged sword of potential and risk. On one hand, the revenue growth trajectory is promising, driven by increasing quarterly sales figures. On the other hand, the company’s profitability is under severe strain, and the negative operating profits and interest coverage ratios suggest that financial health is precarious. Investors should remain cautious, weighing the potential for recovery against the backdrop of operational inefficiencies and rising costs. The high price-to-book value may deter value-focused investors, while the lack of institutional backing could signal underlying concerns. Ultimately, Zota Health Care has the potential for growth if it can stabilize its operations and improve profitability, but significant risks remain that could impact its performance in the near term. Investors would do well to monitor these developments closely before making decisions about their involvement with the stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Zota Health Care Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.44 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 39 | 35 | 37 | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 |
| Expenses | 28 | 34 | 35 | 36 | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 |
| Operating Profit | 1 | 5 | 0 | 1 | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 |
| OPM % | 5% | 12% | 0% | 3% | 3% | 10% | 7% | -3% | -2% | -1% | -8% | 3% | 4% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 2 | 3 | 3 | 4 | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 |
| Profit before tax | -0 | 2 | -3 | -3 | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 |
| Tax % | 119% | 58% | -4% | -15% | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% |
| Net Profit | -1 | 1 | -3 | -3 | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 |
| EPS in Rs | -0.33 | 0.36 | -1.28 | -1.05 | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 |
Last Updated: August 20, 2025, 1:00 am
Below is a detailed analysis of the quarterly data for Zota Health Care Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 7.00 Cr..
- For Expenses, as of Jun 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 100.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears strong and on an upward trend. It has increased from 3.00% (Mar 2025) to 4.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears strong and on an upward trend. It has increased from -14.00 Cr. (Mar 2025) to -13.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 5.00%. The value appears to be increasing, which may not be favorable. It has increased from -10.00% (Mar 2025) to 5.00%, marking an increase of 15.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -13.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -4.81. The value appears to be declining and may need further review. It has decreased from -4.50 (Mar 2025) to -4.81, marking a decrease of 0.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:06 am
| Metric | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 340 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 341 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | -1 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 5% | 1% | 11% | 5% | 4% | -2% | -0% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 11 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 50 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -59 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -58 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -20.50 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% |
YoY Net Profit Growth
| Year | 2011-2012 | 2014-2015 | 2019-2020 | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 33.33% | -50.00% | -100.00% | -166.67% | -133.33% | -307.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -83.33% | -50.00% | -66.67% | 33.33% | -173.81% |
Zota Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2011-2012 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | 72% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 55% |
| 3 Years: | 72% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -24% |
| Last Year: | -36% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:15 am
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 31 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 285 |
| Borrowings | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 181 |
| Other Liabilities | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 109 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
| Fixed Assets | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 251 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 92 |
| Other Assets | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 256 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
Below is a detailed analysis of the balance sheet data for Zota Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 195.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 181.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 140.00 Cr. (Mar 2025) to 181.00 Cr., marking an increase of 41.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2025) to 109.00 Cr., marking an increase of 33.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 606.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 185.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 66.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 38.00 Cr..
- For Other Assets, as of Sep 2025, the value is 256.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 256.00 Cr., marking an increase of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 606.00 Cr.. The value appears strong and on an upward trend. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
Notably, the Reserves (285.00 Cr.) exceed the Borrowings (181.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -1.00 | 1.00 | 3.00 | 8.00 | 5.00 | 1.00 | 0.00 | -38.00 | -87.00 | -146.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 281 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 113 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 219 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -20.68 | -5.59 | -2.29 | 3.58 | -0.09 |
| Diluted EPS (Rs.) | -19.06 | -5.47 | -2.29 | 3.58 | -0.09 |
| Cash EPS (Rs.) | -4.73 | 2.22 | 2.46 | 5.00 | 1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Revenue From Operations / Share (Rs.) | 102.31 | 69.83 | 55.63 | 52.14 | 43.48 |
| PBDIT / Share (Rs.) | -1.28 | 3.37 | 3.69 | 6.53 | 0.76 |
| PBIT / Share (Rs.) | -16.36 | -4.40 | -1.06 | 5.07 | -0.52 |
| PBT / Share (Rs.) | -20.13 | -6.25 | -1.86 | 4.94 | -0.14 |
| Net Profit / Share (Rs.) | -19.81 | -5.55 | -2.29 | 3.54 | -0.08 |
| NP After MI And SOA / Share (Rs.) | -19.70 | -5.55 | -2.29 | 3.54 | -0.08 |
| PBDIT Margin (%) | -1.25 | 4.82 | 6.63 | 12.52 | 1.76 |
| PBIT Margin (%) | -15.99 | -6.30 | -1.90 | 9.72 | -1.20 |
| PBT Margin (%) | -19.67 | -8.95 | -3.35 | 9.47 | -0.34 |
| Net Profit Margin (%) | -19.36 | -7.94 | -4.12 | 6.78 | -0.19 |
| NP After MI And SOA Margin (%) | -19.25 | -7.94 | -4.12 | 6.78 | -0.19 |
| Return on Networth / Equity (%) | -25.21 | -15.94 | -7.18 | 9.93 | -0.31 |
| Return on Capital Employeed (%) | -13.84 | -7.35 | -2.26 | 12.36 | -1.90 |
| Return On Assets (%) | -12.84 | -6.28 | -3.65 | 6.40 | -0.24 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.87 | 0.93 | 0.94 | 1.25 | 1.23 |
| Current Ratio (X) | 1.83 | 1.51 | 2.08 | 2.14 | 3.36 |
| Quick Ratio (X) | 0.77 | 0.78 | 1.05 | 1.33 | 1.81 |
| Inventory Turnover Ratio (X) | 0.20 | 0.26 | 0.49 | 0.71 | 0.75 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -18.01 | -65.37 | 28.24 | -1175.68 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 45.05 | 61.02 | 20.00 | 82.97 |
| Earning Retention Ratio (%) | 0.00 | 118.01 | 165.37 | 71.76 | 1275.68 |
| Cash Earning Retention Ratio (%) | 0.00 | 54.95 | 38.98 | 80.00 | 17.03 |
| Interest Coverage Ratio (X) | -0.33 | 1.82 | 3.62 | 51.22 | 17.16 |
| Interest Coverage Ratio (Post Tax) (X) | -4.26 | -2.00 | -1.46 | 28.78 | -10.27 |
| Enterprise Value (Cr.) | 2311.57 | 1240.13 | 707.78 | 746.47 | 338.81 |
| EV / Net Operating Revenue (X) | 7.89 | 6.87 | 5.06 | 5.69 | 3.17 |
| EV / EBITDA (X) | -630.75 | 142.37 | 76.17 | 45.44 | 179.81 |
| MarketCap / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| Retention Ratios (%) | 0.00 | 118.01 | 165.37 | 71.75 | 1275.68 |
| Price / BV (X) | 10.31 | 13.63 | 8.82 | 8.35 | 5.13 |
| Price / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| EarningsYield | -0.02 | -0.01 | -0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Zota Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -20.68. This value is below the healthy minimum of 5. It has decreased from -5.59 (Mar 24) to -20.68, marking a decrease of 15.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is -19.06. This value is below the healthy minimum of 5. It has decreased from -5.47 (Mar 24) to -19.06, marking a decrease of 13.59.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.73. This value is below the healthy minimum of 3. It has decreased from 2.22 (Mar 24) to -4.73, marking a decrease of 6.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.31. It has increased from 69.83 (Mar 24) to 102.31, marking an increase of 32.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.28. This value is below the healthy minimum of 2. It has decreased from 3.37 (Mar 24) to -1.28, marking a decrease of 4.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is -16.36. This value is below the healthy minimum of 0. It has decreased from -4.40 (Mar 24) to -16.36, marking a decrease of 11.96.
- For PBT / Share (Rs.), as of Mar 25, the value is -20.13. This value is below the healthy minimum of 0. It has decreased from -6.25 (Mar 24) to -20.13, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -19.81. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.81, marking a decrease of 14.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -19.70. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.70, marking a decrease of 14.15.
- For PBDIT Margin (%), as of Mar 25, the value is -1.25. This value is below the healthy minimum of 10. It has decreased from 4.82 (Mar 24) to -1.25, marking a decrease of 6.07.
- For PBIT Margin (%), as of Mar 25, the value is -15.99. This value is below the healthy minimum of 10. It has decreased from -6.30 (Mar 24) to -15.99, marking a decrease of 9.69.
- For PBT Margin (%), as of Mar 25, the value is -19.67. This value is below the healthy minimum of 10. It has decreased from -8.95 (Mar 24) to -19.67, marking a decrease of 10.72.
- For Net Profit Margin (%), as of Mar 25, the value is -19.36. This value is below the healthy minimum of 5. It has decreased from -7.94 (Mar 24) to -19.36, marking a decrease of 11.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -19.25. This value is below the healthy minimum of 8. It has decreased from -7.94 (Mar 24) to -19.25, marking a decrease of 11.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is -25.21. This value is below the healthy minimum of 15. It has decreased from -15.94 (Mar 24) to -25.21, marking a decrease of 9.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is -13.84. This value is below the healthy minimum of 10. It has decreased from -7.35 (Mar 24) to -13.84, marking a decrease of 6.49.
- For Return On Assets (%), as of Mar 25, the value is -12.84. This value is below the healthy minimum of 5. It has decreased from -6.28 (Mar 24) to -12.84, marking a decrease of 6.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.02, marking a decrease of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has decreased from 0.93 (Mar 24) to 0.87, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.83, marking an increase of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.77, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 4. It has decreased from 0.26 (Mar 24) to 0.20, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -18.01 (Mar 24) to 0.00, marking an increase of 18.01.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 45.05 (Mar 24) to 0.00, marking a decrease of 45.05.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 54.95 (Mar 24) to 0.00, marking a decrease of 54.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.33. This value is below the healthy minimum of 3. It has decreased from 1.82 (Mar 24) to -0.33, marking a decrease of 2.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -4.26. This value is below the healthy minimum of 3. It has decreased from -2.00 (Mar 24) to -4.26, marking a decrease of 2.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,311.57. It has increased from 1,240.13 (Mar 24) to 2,311.57, marking an increase of 1,071.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 3. It has increased from 6.87 (Mar 24) to 7.89, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is -630.75. This value is below the healthy minimum of 5. It has decreased from 142.37 (Mar 24) to -630.75, marking a decrease of 773.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 118.01 (Mar 24) to 0.00, marking a decrease of 118.01.
- For Price / BV (X), as of Mar 25, the value is 10.31. This value exceeds the healthy maximum of 3. It has decreased from 13.63 (Mar 24) to 10.31, marking a decrease of 3.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zota Health Care Ltd:
- Net Profit Margin: -19.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -13.84% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -25.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -4.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -19.36%
Fundamental Analysis of Zota Health Care Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Zota House, 2/896, Surat Gujarat 395002 | info@zotahealthcare.com http://www.zotahealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketankumar Chandulal Zota | Non Executive Chairman |
| Mr. Moxesh Ketanbhai Zota | Managing Director |
| Mr. Kamlesh Rajnikant Zota | Whole Time Director |
| Mr. Himanshu Muktilal Zota | Whole Time Director |
| Mr. Manukant Chandulal Zota | Whole Time Director |
| Mr. Laxmi Kant Sharma | Executive Director |
| Mrs. Jaysheeben Nileshkumar Mehta | Ind. Non-Executive Director |
| Ms. Bhumi Maulik Doshi | Ind. Non-Executive Director |
| CA. Vitrag Sureshkumar Modi | Ind. Non-Executive Director |
| Dr. Dhiren Prafulbhai Shah | Ind. Non-Executive Director |
| Dr.(Mrs.) Varsaben Gaurang Mehta | Ind. Non-Executive Director |
| CA. Dhaval Chandubhai Patwa | Ind. Non-Executive Director |
Zota Healthcare Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹475.15 |
| Previous Day | ₹479.10 |
FAQ
What is the intrinsic value of Zota Health Care Ltd?
Zota Health Care Ltd's intrinsic value (as of 08 December 2025) is 445.23 which is 71.80% lower the current market price of 1,579.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,839 Cr. market cap, FY2025-2026 high/low of 1,740/606, reserves of ₹285 Cr, and liabilities of 606 Cr.
What is the Market Cap of Zota Health Care Ltd?
The Market Cap of Zota Health Care Ltd is 4,839 Cr..
What is the current Stock Price of Zota Health Care Ltd as on 08 December 2025?
The current stock price of Zota Health Care Ltd as on 08 December 2025 is 1,579.
What is the High / Low of Zota Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zota Health Care Ltd stocks is 1,740/606.
What is the Stock P/E of Zota Health Care Ltd?
The Stock P/E of Zota Health Care Ltd is .
What is the Book Value of Zota Health Care Ltd?
The Book Value of Zota Health Care Ltd is 103.
What is the Dividend Yield of Zota Health Care Ltd?
The Dividend Yield of Zota Health Care Ltd is 0.06 %.
What is the ROCE of Zota Health Care Ltd?
The ROCE of Zota Health Care Ltd is 17.0 %.
What is the ROE of Zota Health Care Ltd?
The ROE of Zota Health Care Ltd is 36.0 %.
What is the Face Value of Zota Health Care Ltd?
The Face Value of Zota Health Care Ltd is 10.0.